Literature DB >> 24890379

Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart.

James T Thackeray1, Robert A deKemp, Rob S Beanlands, Jean N DaSilva.   

Abstract

BACKGROUND: Positron emission tomography (PET) studies have demonstrated reduced sympathetic neuronal integrity in high-fat diet fed streptozotocin insulin-resistant diabetic rats in parallel with abnormal early-to-atrial transmitral velocity. We hypothesized that administration of anti-glycemic drugs early after diabetes induction would prevent sympathetic neuronal dysfunction. METHODS AND
RESULTS: Male Sprague-Dawley rats fed high-fat diet were administered streptozotocin (45 mg·kg(-1), ip, n = 23) to induce diabetes or vehicle alone (n = 6). Diabetic rats were randomized to receive insulin (4 U·day(-1)), metformin (650 mg·kg(-1)·day(-1)), rosiglitazone (4 mg·kg(-1)·day(-1)), or no treatment 1 week after streptozotocin. Small animal PET imaging using the norepinephrine analog [(11)C]meta-hydroxyephedrine (HED) at baseline and 8 weeks of diabetes determined sympathetic neuronal integrity. Echocardiography assessed cardiac function. Plasma norepinephrine levels were determined in parallel. Ex vivo immunoblotting was performed at the end of the experiment to compare the relative expression of various proteins involved in metabolic and noradrenergic signaling. Insulin restored blood glucose and lipid levels to normal. Despite improved plasma lipid levels, neither metformin nor rosiglitazone reduced blood glucose. At 8 weeks, untreated and treated diabetics displayed a 39%-42% reduction in myocardial HED standardized uptake values (P < .05). In all diabetic groups, plasma norepinephrine was elevated (2.3- to 3.3-fold, P < .05) and norepinephrine reuptake transporter expression reduced (28%-35%, P < .05) compared to non-diabetics. Doppler echocardiography revealed delayed development of prolonged mitral valve deceleration and elevated early-to-atrial filling velocity ratio among treated diabetic rats.
CONCLUSION: Early glycemic treatment of insulin-resistant diabetic rats did not prevent deterioration of sympathetic neuronal integrity though ventricular filling abnormalities were delayed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890379     DOI: 10.1007/s12350-014-9900-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  44 in total

1.  A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.

Authors:  M J Reed; K Meszaros; L J Entes; M D Claypool; J G Pinkett; T M Gadbois; G M Reaven
Journal:  Metabolism       Date:  2000-11       Impact factor: 8.694

Review 2.  Quantification of myocardial blood flow and flow reserve: Technical aspects.

Authors:  Ran Klein; Rob S B Beanlands; Robert A deKemp
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

3.  Reduced CGP12177 binding to cardiac β-adrenoceptors in hyperglycemic high-fat-diet-fed, streptozotocin-induced diabetic rats.

Authors:  James T Thackeray; Maryam Parsa-Nezhad; Miran Kenk; Stephanie L Thorn; Maria Kolajova; Rob S B Beanlands; Jean N DaSilva
Journal:  Nucl Med Biol       Date:  2011-08-09       Impact factor: 2.408

4.  Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.

Authors:  Leonard S Golfman; Christopher R Wilson; Saumya Sharma; Mathias Burgmaier; Martin E Young; Patrick H Guthrie; Melissa Van Arsdall; Julia V Adrogue; Kathleen K Brown; Heinrich Taegtmeyer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-03-29       Impact factor: 4.310

5.  Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.

Authors:  Shi-ying Ding; Zhu-fang Shen; Yue-teng Chen; Su-juan Sun; Quan Liu; Ming-zhi Xie
Journal:  Acta Pharmacol Sin       Date:  2005-05       Impact factor: 6.150

6.  Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes.

Authors:  H Schmid; L A Forman; X Cao; P S Sherman; M J Stevens
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

7.  Myocardial sympathetic innervation in patients with symptomatic coronary artery disease: follow-up after 1 year with neurostimulation.

Authors:  Eva Fricke; Siegfried Eckert; Aristidis Dongas; Harald Fricke; Rainer Preuss; Oliver Lindner; Dieter Horstkotte; Wolfgang Burchert
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

8.  Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats.

Authors:  Laura Raimondi; Petra De Paoli; Edoardo Mannucci; Giuseppe Lonardo; Laura Sartiani; Grazia Banchelli; Renato Pirisino; Alessandro Mugelli; Elisabetta Cerbai
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

9.  Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats.

Authors:  James T Thackeray; Robert A deKemp; Rob S Beanlands; Jean N DaSilva
Journal:  J Nucl Cardiol       Date:  2013-07-11       Impact factor: 5.952

10.  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

Authors:  Robert J Sidell; Mark A Cole; Nicholas J Draper; Martine Desrois; Robin E Buckingham; Kieran Clarke
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

View more
  2 in total

1.  Trying to prevent diabetic cardiovascular autonomic neuropathy: more questions than answers.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2014-06-25       Impact factor: 5.952

2.  Heart Rate Variability as Early Biomarker for the Evaluation of Diabetes Mellitus Progress.

Authors:  Rosa Elena Arroyo-Carmona; Ana Laura López-Serrano; Alondra Albarado-Ibañez; Francisca María Fabiola Mendoza-Lucero; David Medel-Cajica; Ruth Mery López-Mayorga; Julián Torres-Jácome
Journal:  J Diabetes Res       Date:  2016-04-14       Impact factor: 4.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.